What Is Proliferative Index? Definition and What Research Reports

Definition

Proliferative index (also written proliferation index, labelling index or Ki-67 index) is a quantitative measure of the proportion of cells in a tissue section or cytology preparation that are actively progressing through the cell cycle, most commonly expressed as the percentage of tumour or lesional nuclei that stain positive for a proliferation-associated antigen. It is a measurement, not a drug, supplement or administered substance: a pathologist or an image-analysis system counts positive nuclei against total nuclei and reports a percentage. Because the number summarises how fast a cell population is turning over, it appears throughout diagnostic pathology, oncology research and experimental biology as a standard descriptive endpoint.

What class of molecule the index is built on, and where it comes from

The proliferative index itself is a ratio, but the molecule it is usually based on is Ki-67, a large non-histone nuclear protein expressed during the active phases of the cell cycle (G1, S, G2 and mitosis) and essentially absent from resting G0 cells. Ki-67 was originally identified using an antibody raised in Kiel, Germany, which is where the "Ki" in the name comes from; the widely used detection antibody MIB-1 recognises the same antigen in routinely processed, formalin-fixed paraffin-embedded tissue, which is why some papers describe an "MIB-1 proliferative index" rather than a Ki-67 index. Other proliferation readouts exist — mitotic figure counts, PCNA staining and, in cell culture, incorporation assays — but Ki-67/MIB-1 immunohistochemistry is the version most often meant when a paper simply says "proliferative index".

Common ways the index is generated

How the term is used in peptide and growth-factor research

Peptides, peptide hormones and protein growth factors act through receptors that can drive cells into the cell cycle, so investigators frequently need a way to state whether a signalling pathway was associated with more proliferation. The proliferative index provides that endpoint. One published example involved hepatocyte growth factor, a secreted protein ligand, and its receptor tyrosine kinase c-Met: the study of malignant fibrous histiocytoma reported that coexpression of hepatocyte growth factor and c-Met correlated with a high MIB-1 proliferative index (PMID 15239348). In that setting the index was the dependent variable used to describe the biological consequence of ligand–receptor coexpression, rather than anything administered to the tissue.

The index has also been paired with vascular measurements, since angiogenic signalling and proliferation are often studied together. Researchers examining feline post-injection fibrosarcoma reported that microvascular density, endothelial area and the Ki-67 proliferative index correlated with one another within the same tumours (PMID 33379269). Similarly, proliferation has been reported alongside cell death: one investigation of oral cavity lesions evaluated both an apoptotic index and a proliferative index across premalignant and malignant squamous cell lesions (PMID 25709366). These pairings illustrate the general pattern — the proliferative index is one axis in a panel of tissue-level descriptors.

What the Published Literature Reports

Separating benign from malignant

A recurring use in the literature is diagnostic discrimination. The 2016 human pathology study reported that the proliferative index facilitated distinction between benign biliary lesions and intrahepatic cholangiocarcinoma (PMID 27396933). In effusion cytology, researchers compared the Ki-67 proliferative index in reactive mesothelial cells versus metastatic adenocarcinoma cells in serous fluid, a distinction that is notoriously difficult on morphology alone (PMID 23210088). A salivary gland study compared the cellular proliferation index of carcinoma ex-pleomorphic adenoma with that of pleomorphic adenoma (PMID 26312983).

Prognostic and behavioural associations

Other papers examined whether the index tracked with clinical course. A 2018 report on oral squamous cell carcinoma described the proliferative index measured at the invasive tumour front as a potential prognostic indicator (PMID 29422466). In paediatric neuro-oncology, researchers analysed the proliferative index of pilocytic astrocytoma by region of origin and in relation to prediction of clinical behaviour (PMID 30428478). The Ki-67 index has likewise been reported in nodal B-cell lymphoma cytology, where proliferation fraction is part of how these tumours are characterised (PMID 39125462).

As a treatment-response endpoint

Because the index reflects cycling cells at the moment of sampling, it has been used to describe change after intervention in animal tumour work. A 2019 study reported that electrochemotherapy induced tumour regression and decreased the proliferative index in canine cutaneous squamous cell carcinoma (PMID 31676831). That design — measure the index before and after an experimental treatment in an animal model — is the structure most often borrowed when proliferation is used as a readout in preclinical research.

Interpretation Limits: What Studies Report

Published work has repeatedly noted that a proliferative index is context-dependent and that a high number does not by itself indicate malignancy. Researchers examining 65 cases of nodular fasciitis reported a variable Ki-67 proliferative index when compared with fibrosarcoma and fibromatosis, in a lesion that is benign and self-limited (PMID 23531088). Methodology also matters: the study of excised lung neuroendocrine tumours addressed automated quantification precisely because manual counting is labour-intensive and subject to observer variation (PMID 25318848). Sample type is a further variable, since researchers have had to validate the Ki-67 index specifically in cytological rather than histological material (PMID 39125462). Cut-off values, counting region (hot spot versus average field), antibody clone, fixation and scoring method all differ between publications, so indices are not automatically comparable across papers.

Related terms

• Ki-67 index / MIB-1 index — the immunohistochemical form of the proliferative index named after the antigen or detection antibody.
• Labelling index — a generic term for the percentage of cells labelled by any proliferation marker.
• Mitotic index — counted mitotic figures per defined area or number of cells, a morphology-based proliferation measure.
• Apoptotic index — the complementary measure of cell death, reported alongside proliferation in oral squamous lesion research (PMID 25709366).
• Microvascular density — a vascular descriptor reported to correlate with the Ki-67 index in one feline fibrosarcoma study (PMID 33379269).

Summary of the entry

In plain terms, proliferative index answers one narrow question: what share of the cells in this sample were dividing when the sample was taken? It is derived from staining for Ki-67, a nuclear protein present only in cycling cells, and is reported as a percentage. Published studies have used it to help separate benign from malignant lesions, to describe associations with tumour behaviour, to link growth-factor signalling with proliferation, and to document change after experimental treatment in animal models. This page is for educational purposes only and is not medical advice; consult a licensed physician regarding any health condition, diagnostic test result or medical decision.

References

• Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma (Human Pathology, 2016)
• Assessment of Ki-67 Proliferative Index in Cytological Samples of Nodal B-Cell Lymphomas (Diagnostics, 2024)
• Proliferative Index in Pediatric Pilocytic Astrocytoma by Region of Origin and Prediction of Clinical Behavior (Pediatric Neurosurgery, 2018)
• Microvascular Density, Endothelial Area, and Ki-67 Proliferative Index Correlate Each Other in Cat Post-Injection Fibrosarcoma (Cells, 2020)
• Apoptotic index and proliferative index in premalignant and malignant squamous cell lesions of the oral cavity (Journal of International Oral Health, 2015)
• Proliferative index using Ki-67 index in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid (Advanced Biomedical Research, 2012)
• Electrochemotherapy induces tumor regression and decreases the proliferative index in canine cutaneous squamous cell carcinoma (Scientific Reports, 2019)
• Proliferative Index in Invasive Tumor Front of Oral Squamous Cell Carcinoma: A Potential Prognostic Indicator (The Journal of Contemporary Dental Practice, 2018)
• Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung (Diagnostic Pathology, 2014)
• Coexpression of hepatocyte growth factor and its receptor c-Met correlates with high MIB-1 proliferative index in malignant fibrous histiocytoma (Pathology, Research and Practice, 2004)
• Variable Ki67 proliferative index in 65 cases of nodular fasciitis, compared with fibrosarcoma and fibromatosis (Diagnostic Pathology, 2013)
• Cellular Proliferation Index between Carcinoma Ex-Pleomorphic Adenoma and Pleomorphic Adenoma (Brazilian Dental Journal, 2015)